• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Revelation Biosciences Inc.

    1/20/26 8:31:30 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $REVB alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    REVELATION BIOSCIENCES, INC.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    76135L705

    (CUSIP Number)


    12/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    76135L705


    1Names of Reporting Persons

    SABBY MANAGEMENT, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    605,702.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    605,702.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    605,702.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.6 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP No.
    76135L705


    1Names of Reporting Persons

    Hal Mintz
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    FLORIDA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    605,702.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    605,702.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    605,702.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.6 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    76135L705


    1Names of Reporting Persons

    Sabby Volatility Warrant Master Fund, Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    605,702.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    605,702.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    605,702.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.6 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    REVELATION BIOSCIENCES, INC.
    (b)Address of issuer's principal executive offices:

    4660 LAJOLLA VILLAGE DRIVE, SUITE 100, SAN DIEGO, CALIFORNIA, 92122
    Item 2. 
    (a)Name of person filing:

    Sabby Volatility Warrant Master Fund, Ltd. Sabby Management, LLC Hal Mintz
    (b)Address or principal business office or, if none, residence:

    Sabby Volatility Warrant Master Fund, Ltd. c/o Captiva (Cayman) Ltd Governors Square, Bldg 4, 2nd Floor 23 Lime Tree Bay Avenue P.O. Box 32315 Grand Cayman KY1-1209 Cayman Islands Sabby Management, LLC 1011 Links Dr. Miami Beach, FL 33109 Hal Mintz c/o Sabby Management, LLC 1011 Links Dr. Miami Beach, FL 33109
    (c)Citizenship:

    Sabby Volatility Warrant Master Fund, Ltd. - Cayman Islands Sabby Management, LLC - Delaware, USA Hal Mintz - USA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    76135L705
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Sabby Volatility Warrant Master Fund, Ltd. - 605,702 Sabby Management, LLC - 605,702 Hal Mintz - 605,702
    (b)Percent of class:

    Sabby Volatility Warrant Master Fund, Ltd. - 9.56% Sabby Management, LLC - 9.56% Hal Mintz - 9.56%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    605,702

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    605,702

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    SABBY MANAGEMENT, LLC
     
    Signature:/s/ Robert Grundstein
    Name/Title:COO
    Date:01/20/2026
     
    Hal Mintz
     
    Signature:/S/ HAL MINTZ
    Name/Title:HAL MINTZ
    Date:01/20/2026
     
    Sabby Volatility Warrant Master Fund, Ltd.
     
    Signature:/s/ Harry Thompson
    Name/Title: Harry Thompson
    Date:01/20/2026
    Get the next $REVB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $REVB

    DatePrice TargetRatingAnalyst
    2/17/2022$12.00Buy
    Roth Capital
    More analyst ratings

    $REVB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on Revelation Biosciences with a new price target

    Roth Capital initiated coverage of Revelation Biosciences with a rating of Buy and set a new price target of $12.00

    2/17/22 8:17:25 AM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REVB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Rolke James was granted 532,829 shares, increasing direct ownership by 133% to 933,489 units (SEC Form 4)

    4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)

    1/12/26 5:21:07 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Zygmont Chester Stanley Iii was granted 78,145 shares (SEC Form 4)

    4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)

    1/12/26 5:17:29 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Carver Jennifer was granted 41,981 shares, increasing direct ownership by 268% to 57,669 units (SEC Form 4)

    4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)

    1/12/26 5:12:11 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REVB
    SEC Filings

    View All

    $REVB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Revelation Biosciences Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

    1/21/26 7:01:18 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Revelation Biosciences Inc.

    SCHEDULE 13G - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)

    1/20/26 8:31:30 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Revelation Biosciences Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

    8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

    12/3/25 5:01:56 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025

    Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its financial results for the three and six months ended June 30, 2025. Corporate Highlights Completed dosing of patients in PRIME Phase 1b Clinical Study of Gemini in CKD Patients Received gross proceeds of $4 million from public offering in May 2025 "The Revelation team continues to strategically maximize its financial resources to achieve our stated objectives and advance the Gemini program," said James Rolke, Chief Executive Officer of Revelation. "We look forward to announcing data fr

    8/8/25 6:30:00 AM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Revelation Biosciences, Inc. Congratulates Its Former Chairman of the Board, George Tidmarsh, on His Appointment as the Head of the FDA Center for Drug Evaluation and Research

    Revelation Biosciences, Inc. (NASDAQ:REVB) the "Company" or "Revelation") a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, today congratulates its former chairman and shareholder, George Tidmarsh, MD, PhD, who has been selected to head the FDA Center for Drug Evaluation and Research. "George was the chairman of the board of our company, Revelation Biosciences, Inc., as well as one of the founders," said James Rolke, President and CEO, Revelation. "We wish to thank George for his guidance and support during his tenure on the Revelation board as well as for the time we worked together at La Jolla Pharmaceutical Company." Dr. Tidmarsh trained a

    7/24/25 9:00:00 AM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study

    – Sample analysis and data collection ongoing – – Data expected during Q3 2025 – Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, today announced dosing has been completed for the PRIME (PReconditioning IMmunostimulatory Evaluation) Phase 1b clinical study of escalating doses of intravenously administered Gemini in patients with Stage 3 and 4 Chronic Kidney Disease (CKD). As planned, a total of 5 cohorts were enrolled at 3 clinics in the United States. Several study data sets are expected during Q3 2025: these will include safety parameters, changes in hematologic pa

    7/16/25 9:00:00 AM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REVB
    Financials

    Live finance-specific insights

    View All

    Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025

    Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its three months ended March 31, 2025 financial results. Corporate Highlights Announced a new indication for Gemini in severe burn patients Released data showing Gemini priming attenuated inflammation in peripheral blood mononuclear cells Completed dosing of first patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients "While we continue to expand the pipeline here at Revelation, we are excited to continue our collaboration with Vanderbilt and Dr. Bohannon in the area of severe bu

    5/8/25 4:15:00 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024

    Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its three and twelve months ended December 31, 2024 financial results. Corporate Highlights Announced dosing of first patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients Announced start of its PRIME Phase 1b Clinical Study of Gemini in CKD Patients Announced FDA Acceptance of Gemini IND Received net proceeds of $3.7 million from the exercise of warrants in December 2024 "We made significant progress at the end of last year and hope to continue that pace in 2025," said James

    3/6/25 4:15:00 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024

    Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, today reported its three and nine months ended September 30, 2024 financial results. Corporate Highlights Completed GMP manufacture of Gemini clinical drug supply Received net proceeds of $3.8 million from the exercise of warrants in August 2024 Announced Gemini induces dose dependent significant increases in IL-10 in healthy volunteers "The Revelation team continues to make significan

    11/8/24 4:15:00 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REVB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Revelation Biosciences Inc. (Amendment)

    SC 13G/A - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)

    2/13/24 8:12:05 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Revelation Biosciences Inc.

    SC 13G - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)

    1/3/24 8:36:37 AM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Revelation Biosciences Inc.

    SC 13G - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)

    2/21/23 4:49:56 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REVB
    Leadership Updates

    Live Leadership Updates

    View All

    Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors

    Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced the retirement of George F. Tidmarsh, MD, PhD from the Company's Board of Directors. "The team at Revelation wholeheartedly thanks Dr. Tidmarsh for his guidance and support over the past 5 years," said James Rolke, Chief Executive Officer of Revelation. "While he will be missed, we wish him the best of luck in his newest endeavor." "The Revelation team is dedicated to developing innovative therapies to improve the clinical outcomes for patients in need," said Dr. Tidmarsh. "I thank them for their passio

    5/23/25 4:05:00 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025

    – A vote for Proposal 2 saves the Company over $200,000 per year – Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, wants to remind all shareholders to vote their proxies for the January 17, 2025 special meeting of stockholders. In particular, a vote for Proposal 2, the redomicile of the Company from Delaware to Nevada will save the Company at least $200,000.00 per year in franchise tax fees. All proposals in the proxy are important and the Board of Directors has suggested a vote for all proposals. Please vote by calling Advantage Pr

    1/13/25 6:00:00 AM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors

    Revelation Biosciences Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today announced the appointment of Lakhmir Chawla M.D. to the Company's Board of Directors (Board). "We are excited to welcome Dr. Chawla as an independent director to our Board," said James Rolke, Chief Executive Officer of Revelation. "Dr. Chawla brings decades of expertise and leadership in key areas such as nephrology, critical care medicine, drug development and strategic implementation. I am confident that he will provide valuable perspectives as we continue to execute our str

    10/2/23 9:00:00 AM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care